The trial will assess orally administered pritelivir for the treatment of drug resistant mucocutaneous herpes simplex virus (HSV) infections in the immunocompromised.
Researchers from NASA’s Johnson Space Center have discovered that dormant herpes viruses reactivate during spaceflight, leading to an urgent need to develop counter-measures, including vaccination, to ensure the success of deep-space missions.